Nasdaq OTC Indices USA | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (39)

Latest Posts

About This Stock More About This Stock
3 Downgraded Stocks To Sell In A Shaky Market
Article By: StockNews
Friday, September 17, 2021 12:37 PM EDT
Over the last two weeks, the market has been steadily moving lower. There are increasing signs of economic stress in terms of supply chain issues, coronavirus case counts continuing to rise, and signs that the consumer may be tapped out.
In this article: NERV, MUX, AREC
Read
4 Biotech Stocks In Neurology, As Biotechs March On
Article By: Tarun Chandra, CFA
Saturday, December 21, 2019 5:20 PM EDT
In a space of 2-months, biotechs have gone from recording yearly lows in early October, to recording 2019 highs.
In this article: NBIX, ACAD, KRTX, NERV
Read
The Week In Charts: Your Trading Success Might All Boil Down To This One Thing
Video By: Dave Landry
Sunday, October 7, 2018 7:36 AM EDT
In this episode, Dave discusses how your trading success could boil down to just two words. And, last but not least, he fielded your trading questions and analyzed your favorite stock picks.
In this video: ANET, UROV, MRNS, SQ, TLT, SPY, IWM, NERV, USO, UUP, XLF
Watch
Minerva Neurosciences Announces Pricing Of Public Offering Of Common Stock
Article By: NASDAQ GlobeNewswire
Wednesday, June 28, 2017 8:53 PM EDT
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $7.75 per share.
In this article: NERV
Read
Minerva Neurosciences Shares Soar On New Amended Agreement With Janssen
Article By: TickerTV
Thursday, June 1, 2017 9:16 AM EDT
NERV opened trading yesterday at $8.55 which was exactly the same as the previous day’s trading close. Shares closed trading yesterday at $8.25 and spiked up after market to $9.55, equivalent to a 16% increase from the closing price.
In this article: NERV
Read

Latest Tweets for $NERV

No tweets yet!

PARTNER HEADLINES